The activation of lymphocytes is a process involving multiple signals. The immune system needs to maintain an optimal balance between autoimmune disease prevention and tumor elimination. This balance is regulated by a series of costimulatory and inhibitory receptors/ligands, and the ligand/receptor pathways involved in this balance are called immune checkpoints. Immune checkpoint inhibitors are antibody drugs developed for the corresponding immune checkpoints, which mainly reactivate the anti-tumor immune response by destroying co-suppressive T cell signaling.
The amino acid sequence homology between the immune checkpoint genes of ordinary mice and the corresponding human genes is generally about 60%. However, under normal circumstances, antibodies that recognize human immune checkpoint proteins cannot identify the corresponding proteins in mice - which may be resolved with the humanization of mouse immune checkpoint genes.
✔ Double-Humanized PD-1/VISTA Mouse Model
hPD-1 & VISTA expression in mice has a normal physiological expression and regulation mode. The double-humanized PD-1 and VISTA mouse model (hPD-1/hVISTA) was generated by intercrossing hPD-1 and hVISTA mice.
✔ Double-Humanized PD-1/CTLA-4 Mouse Model
hPD-1 & CTLA-4 expression in mice has a normal physiological expression and regulation mode. The double-humanized PD-1 and CTLA-4 mouse model (hPD-1/hCTLA-4) was generated by intercrossing hPD-1 and hCTLA-4 mice.
✔ Double-Humanized CTLA-4/LAG3 Mouse Model
hCTLA-4 & hLAG3 expression in mice has a normal physiological expression and regulation mode，all regulated by endogenous mouse promotersh. The double-humanized CTLA-4 and LAG3 mouse model (hCTLA-4/hLAG3) was generated by intercrossing hCTLA-4 and hLAG3 mice.
In 2020, Cyagen reached a strategic partnership with genOway. Founded in 1999, genOway is the preferred reliable supplier of laboratory mice for scientific research and medicine in Europe and America. Double-targeted Immune Checkpoint (ICP) mice are one of the selected mice product introduced by Cyagen in the cooperation - Why do we recommend genOway's mouse model?
1. Robust verification by both Industry leaders and literatures: Services and products from genOway have been cited many times in high-impact academic journals such as Cell, Nature, Science, and PNAS. As a partner of the the EU Research and Innovation programme (Horizon 2020), its immune checkpoint (ICP) and severe combined immunodeficient (SCID) model series have been jointly verified by the company and its partners worldwide, including leaders in the fields of immuno-oncology and immunotherapy, large pharmaceutical companies, biotechnology companies, research institutions, and more.
2. Leading supplier of genetically engineered animal models in Europe and the United States: genOway has obtained patent licenses for all its technologies used to construct models, and is the only supplier that can guarantee you the opportunity to operate all the models on your own. Founded in 1999, genOway has 21 years of experience in animal model services, the company now has developed into a leader in the field of customized, genetically modified (GM) mouse, rat, and cell model creation, while serving international pharmaceuticals (Novartis, Pfizer, BMS, Janssen, and more.) and world-famous academic research centers (National Institutes of Health (NIH), Institut Pasteur, etc.) with their services.
3. Comprehensive Intellectual Property (IP) Protection: Clear and independent IP rights are an essential facet of successful drug discovery projects. genOway provides various disease animal models with a wide range of patents and license agreements to ensure that the IP rights of the model are clear. This guarantees you freedom to operate (FTO) along with the provisions of the model.
4. Specific Model Genetic Background: All models are provided on a specific genetic strain background, of accurate and traceable sources, and includes periodic genetic testing performed in colony maintenance to ensure the reproducibility of your research results.